Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study

Abstract

Objective

To pilot test a mobile health intervention using a CONnected CUstomized Treatment Platform that integrates a connected electronic adherence monitoring smartbox and an early warning system of non-adherence with bidirectional automated texting feature and provider alerts.

Methods

In total, 29 adult women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer and a prescription for palbociclib were asked to complete a survey and participate in a CONnected CUstomized Treatment Platform intervention, including use of a smartbox for real-time adherence monitoring, which triggered text message reminders for any missed or extra dose, and referrals to (a) participant's oncology provider after three missed doses or an episode of over-adherence, or (b) a financial navigation program for any cost-related missed dose. Use of smartbox, number of referrals, palbociclib adherence, CONnected CUstomized Treatment Platform usability measured by System Usability Scale, and changes in symptom burden and quality of life were assessed.

Results

Mean age was 57.6 and 69% were white. The smartbox was used by 72.4% of participants, with palbociclib adherence rate of 95.8%±7.6%. One participant was referred to oncology provider due to missed doses and one was referred to financial navigation. At baseline, 33.3% reported at least one adherence barrier including inconvenience to get prescription filled, forgetfulness, cost, and side effects. There were no changes in self-reported adherence, symptom burden or quality of life over 3 months. CONnected CUstomized Treatment Platform usability score was 61.9 ± 14.2.

Conclusion

The CONnected CUstomized Treatment Platform interventions is feasible, resulting in a high palbociclib adherence rate without any decline in overtime. Future efforts should focus on improving usability.

Keywords

Metastatic breast cancer mobile health adherence palbociclib

Get full access to this article

View all access options for this article.

References

Finn

Crown

Lang

, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16: 25–35. 2014/12/20.

Finn

Martin

Rugo

, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925–1936. 2016/12/14.

Turner

Slamon

, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018; 379: 1926–1936. 2018/10/23.

Cristofanilli

Rugo

, et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): updated analyses from PALOMA-3. J Clin Oncol 2021; 39: abstr 1000.

Husinka

Koerner

Miller

, et al. Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. J Drug Assess 2021; 10: 27–34. 2021/01/09.

Anderson

. How much does Ibrance cost? Available at: https://www.drugs.com/medical-answers/ibrance-cost-3539523/ Accessed on April 14, 2022.

Lee

Koopmeiners

Rhee

, et al. Mobile Phone Text Messaging Intervention for Cervical Cancer Screening: Changes in Knowledge and Behavior Pre-Post Intervention. J Med Internet Res 2014; 16: e196.

Jordan

Thomas

McClelland

, et al. Usability Evaluation in Industry. London: Taylor & Francis, Inc, 1996.

Peipert

Badawy

Baik

, et al. Development of the NIH patient-reported outcomes measurement information system (PROMIS) medication adherence scale (PMAS). Patient Prefer Adherence 2020; 14: 971–983. 2020/07/02.

10.

Brady

Cella

, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997; 15: 974–986. 1997/03/01.

11.

Cella

Yount

Rothrock

, et al. The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care 2007; 45: S3–S11. 2007/04/20.

12.

Symons

Swanson

McGuigan

, et al. A tool for self-assessment of communication skills and professionalism in residents. BMC Med Educ 2009; 9: 1. 2009/01/10.

13.

de Souza

Yap

Hlubocky

, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014; 120: 3245–3253. 2014/06/24.

14.

de Souza

Yap

Wroblewski

, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer 2017; 123: 476–484. 2016/10/08.

15.

Chew

Bradley

Boyko

. Brief questions to identify patients with inadequate health literacy. Fam Med 2004; 36: 588–594. 2004/09/03.

16.

daCosta DiBonaventura

Copher

Basurto

, et al. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits 2014; 7: 386–396. 2014/12/20.

17.

Conley

McIntyre

Pensak

, et al. Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study. Breast Cancer Res Treat 2022; 192: 385–399. 2022/01/09.

18.

Kish

Ward

Garofalo

, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 2018; 20: 37. 2018/05/04.

19.

Finn

Crown

Ettl

, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016; 18: 67. 2016/06/29.

20.

Hortobagyi

Stemmer

Burris

, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738–1748. 2016/11/03.

21.

Roberts

Reeder-Hayes

. Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health 2015; 105: e4–e15. 2015/04/24.

22.

Lin

Clark

, et al. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat 2017; 165: 247–260. 2017/06/03.

23.

Hershman

Unger

Hillyer

, et al. Randomized trial of text messaging to reduce early discontinuation of adjuvant aromatase inhibitor therapy in women with early-stage breast cancer: SWOG S1105. J Clin Oncol 2020; 38: 2122–2129. doi:10.1200/jco.19.02699

24.

Mauro

Mathews

Sredzinski

. Effect of a smart pill bottle and pharmacist intervention on medication adherence in patients with multiple myeloma new to lenalidomide therapy. J Manag Care Spec Pharm 2019; 25: 1244–1254. 2019/10/31.

25.

Mougalian

Epstein

Jhaveri

, et al. Bidirectional text messaging to monitor endocrine therapy adherence and patient-reported outcomes in breast cancer. JCO Clin Cancer Inform 2017; 1: 1–10. 2017/11/01.

26.

Greer

Amoyal

Nisotel

, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016; 21: 354–376. 2016/02/28.

27.

Shankaran

Unger

Darke

, et al. S1417CD: a prospective multicenter cooperative group-led study of financial hardship in metastatic colorectal cancer patients. J Natl Cancer Inst 2022; 114: 372–380. 2022/01/05.

28.

Usability.gov. System Usability Scale (SUS) [Internet]. Vol. 12. 2014. p. 2017. Available from: https://www.usability.gov/how-to-and-tools/methods/system-usability-scale.html Accessed on April 22, 2022.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB